翻訳と辞書 |
Pidilizumab
Pidilizumab (formerly CT-011) is a monoclonal antibody developed by CureTech for the treatment of cancer and infectious diseases.〔(Statement On A Nonproprietary Name Adopted By The USAN Council - Pidilizumab ), ''American Medical Association''- needs login.〕 Pidilizumab binds to the PD-1 immune checkpoint molecule. Mechanistically, the binding of pidilizumab to PD-1 results in the attenuation of apoptotic processes in lymphocytes, primarily effector/memory T cells. ==Clinical trials== It had encouraging results by 2011 from phase II clinical trials for diffuse large B-cell lymphoma.〔(Teva Invests $19M More in CureTech After Positive Phase II DLBCL Data. Sept 2011 )〕 A phase II open-label study in combination for relapsed follicular lymphoma found good results compared to usual response rates. An add-on trial for multiple myeloma is ongoing.
抄文引用元・出典: フリー百科事典『 ウィキペディア(Wikipedia)』 ■ウィキペディアで「Pidilizumab」の詳細全文を読む
スポンサード リンク
翻訳と辞書 : 翻訳のためのインターネットリソース |
Copyright(C) kotoba.ne.jp 1997-2016. All Rights Reserved.
|
|